<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240314</url>
  </required_header>
  <id_info>
    <org_study_id>AAV9 Dup2 U7</org_study_id>
    <nct_id>NCT04240314</nct_id>
  </id_info>
  <brief_title>AAV9 U7snRNA Gene Therapy to Treat Boys With DMD Exon 2 Duplications.</brief_title>
  <official_title>Phase I/IIa Systemic Gene Delivery Clinical Trial of scAAV9.U7.ACCA for Exon 2 Duplication-Associated Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Megan Waldrop</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Audentes Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, single dose clinical trial of scAAV9.U7.ACCA via peripheral limb vein injection
      for Duchenne muscular dystrophy boys who have a duplication of exon 2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed clinical trial is a systemic (intravenous) delivery of scAAV9.U7.ACCA for DMD
      patients with a duplication of exon 2 in the DMD gene. Preclinical data shows that the small
      nuclear RNA (snRNA) construct delivered by the scAAV9.U7.ACCA vector causes significant
      skipping of exon 2, resulting in exclusion of the exon from the mature messenger RNA (mRNA)
      with a high degree of efficiency, leading to mRNA containing only a single exon 2 (wild type
      [WT] mRNA) or no copies of exon 2 (Del2 mRNA). Translation of the wild-type mRNA results in
      entirely normal dystrophin protein, whereas translation of the Del2 mRNA via translational
      initiation of an internal ribosome entry sequence, or IRES) results in a highly functional
      isoform expressed in patients known to walk into their eighth decade.

      The study is designed as an open-label trial to assess safety and obtain preliminary efficacy
      data. scAAV9.U7.ACCA will be delivered to the systemic circulation via peripheral limb vein.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 15, 2020</start_date>
  <completion_date type="Anticipated">January 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This trial will deliver the minimal efficacious dose as determined by preclinical studies and approved by the FDA to determine safety and target engagement.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monitoring for the development of unacceptable toxicity.</measure>
    <time_frame>2 years</time_frame>
    <description>Unacceptable toxicity is defined as the occurrence of two or more unexpected Grade III or higher treatment-related toxicities, as defined by CTCAE 5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in dystrophin expression from baseline following treatment with scAAV9.U7.ACCA.</measure>
    <time_frame>1 year</time_frame>
    <description>Expression of dystrophin will be measured by immunofluorescent staining in muscle biopsies taken before and after gene therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dystrophin expression from baseline following treatment with scAAV9.U7.ACCA.</measure>
    <time_frame>1 year</time_frame>
    <description>Expression of dystrophin will be quantified by western blotting in muscle biopsies taken before and after gene therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in exon 2 inclusion in the dystrophin mRNA transcript.</measure>
    <time_frame>1 year</time_frame>
    <description>Exon 2 inclusion will be measured using RT-PCR analysis.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (Minimal Efficacious Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Minimal Effective Dose (MED) will be delivered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>scAAV9.U7.ACCA</intervention_name>
    <description>A single dose of scAAV9.U7.ACCA will be systemically delivered via a peripheral vein injection.</description>
    <arm_group_label>Cohort 1 (Minimal Efficacious Dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 6 months and less than 14 years

          -  Confirmed duplication of exon 2 in the DMD gene using a clinically accepted technique
             that completely defines the mutation

          -  Pre-ambulant (not yet walking) or ambulant (as defined by the ability to walk 10
             meters without assistance)

          -  Males of any ethnic group will be eligible

          -  Ability to cooperate with muscle testing

          -  In subjects age 4 and above, stable dose and regimen of corticosteroid therapy
             (prednisone, deflazacort, or their generic forms) for at least 12 weeks prior to gene
             transfer.

        Exclusion Criteria:

          -  Active viral infection based on clinical observations

          -  Symptoms or signs of cardiomyopathy, including:

               1. Dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales
                  at the base of the lungs

               2. Echocardiogram with ejection fraction below 40%

          -  Serological evidence of HIV infection, or Hepatitis B or C infection

          -  Diagnosis of (or ongoing treatment for) an autoimmune disease

          -  Persistent leukopenia or leukocytosis (WBC ≤ 3.5 K/µL or ≥ 20.0 K/µL) or an absolute
             neutrophil count &lt; 1.5K/µL

          -  Concomitant illness or requirement for chronic drug treatment that in the opinion of
             the SI creates unnecessary risks for gene transfer

          -  AAV9 binding antibody titers ≥ 1:400 as determined by ELISA immunoassay

          -  Abnormal laboratory values in the clinically significant range as listed in Table 7,
             based upon normal values in the Nationwide Children's Hospital Laboratory.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Megan Waldrop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wein N, Vulin A, Falzarano MS, Szigyarto CA, Maiti B, Findlay A, Heller KN, Uhlén M, Bakthavachalu B, Messina S, Vita G, Passarelli C, Brioschi S, Bovolenta M, Neri M, Gualandi F, Wilton SD, Rodino-Klapac LR, Yang L, Dunn DM, Schoenberg DR, Weiss RB, Howard MT, Ferlini A, Flanigan KM. Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice. Nat Med. 2014 Sep;20(9):992-1000. doi: 10.1038/nm.3628. Epub 2014 Aug 10. Erratum in: Nat Med. 2015 Apr;21(4):414. Nat Med. 2015 May;21(5):537. Brioschi, Simona [added]; Bovolenta, Matteo [added]; Neri, Marcella [added].</citation>
    <PMID>25108525</PMID>
  </reference>
  <reference>
    <citation>Vulin A, Wein N, Simmons TR, Rutherford AM, Findlay AR, Yurkoski JA, Kaminoh Y, Flanigan KM. The first exon duplication mouse model of Duchenne muscular dystrophy: A tool for therapeutic development. Neuromuscul Disord. 2015 Nov;25(11):827-34. doi: 10.1016/j.nmd.2015.08.005. Epub 2015 Aug 11.</citation>
    <PMID>26365037</PMID>
  </reference>
  <reference>
    <citation>Gurvich OL, Maiti B, Weiss RB, Aggarwal G, Howard MT, Flanigan KM. DMD exon 1 truncating point mutations: amelioration of phenotype by alternative translation initiation in exon 6. Hum Mutat. 2009 Apr;30(4):633-40. doi: 10.1002/humu.20913.</citation>
    <PMID>19206170</PMID>
  </reference>
  <reference>
    <citation>Flanigan KM, Dunn DM, von Niederhausern A, Howard MT, Mendell J, Connolly A, Saunders C, Modrcin A, Dasouki M, Comi GP, Del Bo R, Pickart A, Jacobson R, Finkel R, Medne L, Weiss RB. DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy. Neuromuscul Disord. 2009 Nov;19(11):743-8. doi: 10.1016/j.nmd.2009.08.010. Epub 2009 Sep 29.</citation>
    <PMID>19793655</PMID>
  </reference>
  <reference>
    <citation>Vulin A, Barthélémy I, Goyenvalle A, Thibaud JL, Beley C, Griffith G, Benchaouir R, le Hir M, Unterfinger Y, Lorain S, Dreyfus P, Voit T, Carlier P, Blot S, Garcia L. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther. 2012 Nov;20(11):2120-33. doi: 10.1038/mt.2012.181. Epub 2012 Sep 11.</citation>
    <PMID>22968479</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Megan Waldrop</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

